Threshold Pharmaceuticals (THLD) Reports Positive Clinical Trials of TH-302 for Solid Tumors
More News related to THLD
- Threshold Pharmaceuticals Presents Interim Prostate Cancer Data From Early Stage Trials of TH-302
- Threshold to Present at Lazard Capital Markets Healthcare Conference
- Threshold Pharmaceuticals Announces Clinical Development Results for Cancer Candidate TH-302
- Threshold Pharmaceuticals Presents Interim Data From a Phase 1/2 Clinical Trial of TH-302 at Sarcoma Meeting
- Threshold Pharmaceuticals Reports Third Quarter 2009 Financial Results
More News related to Corporate News
- Capstone Turbine (CPST) Receives Two Clean Energy Project Awards
- Sucampo Pharma (SCMP) Presents Additional Clinical Data for Lubiprostone
- Longtop Financial (LFT) Signs Contract with Chinese Life Insurance Group to Upgrade CDW
- Given Imaging (GIVN) Announces the Degree of Impact the PillCam SB has on GI Patients, Crohn's Disease
- NiSource (NI) Comments on Moody's Affirmation of NiSource's Credit Rating
Threshold Pharmaceuticals, Inc. (Nasdaq: THLD) previously announced on May 30, 2009, clinical trial results related to its clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the American Society for Clinical Oncology (ASCO) being held May 29 to June 2, 2009, at the Orange County Convention Center in Orlando, FL.
"The results from these studies are encouraging to us and to our advisors. The monotherapy trial demonstrated an attractive safety profile for TH-302 with minimal evidence of myelosuppression and, as previously reported, signs of therapeutic activity in small cell lung cancer and metastatic melanoma. In the combination therapy trials, TH-302 appears to be safely combined with labeled doses and schedules of gemcitabine, docetaxel, pemetrexed, and doxorubicin. Additionally, we have observed partial responses in combination with all four chemotherapies with some patients experiencing durable responses extending out over six months," said John Curd, M.D., Threshold's president and chief medical officer. "Though these clinical trials are in an early stage of development with a relatively small number of patients, we remain hopeful that TH-302 may provide an additional treatment option for patients living with cancer."
Results from thirty-one patients in a Phase 1 clinical trial evaluating the safety and preliminary efficacy of TH-302 in patients with advanced solid tumors were presented at a poster session on May 30, 2009. The clinical trial was designed with an initial accelerated titration design followed by a standard dose escalation schema. The trial has completed the dose escalation component, reached the maximum tolerated dose (MTD) and is currently enrolling patients in the expansion phase of the trial at the MTD. [SM]
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
